Published in Medical Letter on the CDC and FDA, March 28th, 2010
"Overall, our exploratory CBMN correctly classified 97 of 112 (86.6%) compounds in the CA assay....
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.